Amyloid beta protein is predominant in senile plaques, the neuropathologic hallmarks of
Alzheimer disease. Researchers in Winnipeg have shown that this protein can overstimulate …

Progressive cerebral deposition of the amyloid β-protein (Aβ) in brain regions serving
memory and cognition is an invariant and defining feature of Alzheimer disease. A highly …

The second generation of therapeutic strategies for Alzheimer's disease (AD) embraces the
Amyloid Hypothesis, which asserts that through a series of events not completely …

Neuritic plaques composed of amyloid beta-protein (A beta) are an early and invariant
neuropathological feature of Alzheimer's disease (AD). The current preclinical search for …

A new class of drug shows promise of in future offering a new form of treatment for
Alzheimer's disease, as well as helping fight multiple sclerosis and traumatic brain injury …

Alzheimer's disease (AD) is characterized by the deposition of amyloid in the extracellular
compartment of the brain in the form of congophilic amyloid angiopathy (CAA) and amyloid …

ALZHEIMER'S DISEASE (AD) was first described in a 51-year-old patient in 1907 by the
Bavarian psychiatrist, Alois AlzheimerL The disease begins with loss of short-term memory; …

Alzheimer's disease (AD) pathogenesis is widely believed to be driven by the production
and deposition of the amyloid-β peptide (Aβ). For many years, investigators have been …

Alzheimer's disease is a devastating degenerative disorder of the brain for which there is no
cure or effective treatment. Although the etiology of Alzheimer's disease is not fully …

An estimated 5.3 million Americans of all ages have Alzheimer's disease. This figure
includes 5.1 million people aged 65 and older and 200 000 individuals under the age of 65 …